Garenoxacin pharmacokinetics in patients undergoing maintenance hemodialysis

Abstract

MH patients receiving 200 mg GRNX once daily for infection showed a reduced C but similar AUC compared with healthy individuals. While this study evaluated the effect of GRNX treatment, further research is needed to assess the accumulation of GRNX and the impact of continuous administration on its pharmacokinetics, as well as to prevent the development of resistant mutants.

Severe and Recurrent Hypoglycemia Caused by Garenoxacin in a Patient not Taking Hypoglycemic Drugs

“…As shown in ( Table ), we measured the garenoxacin concentration several times. The removal of garenoxacin by hemodialysis is reported to occur at a rate of 1.5% to 11.5% ( 5 ). Aoyama et al reported that administration of 200 mg garenoxacin once daily in 6 patients undergoing maintenance hemodialysis resulted in an average maximum plasma garenoxacin concentration of 3.0±1.12 μg/mL ( 5 ).…”

“…The removal of garenoxacin by hemodialysis is reported to occur at a rate of 1.5% to 11.5% ( 5 ). Aoyama et al reported that administration of 200 mg garenoxacin once daily in 6 patients undergoing maintenance hemodialysis resulted in an average maximum plasma garenoxacin concentration of 3.0±1.12 μg/mL ( 5 ). Despite a 72-h interval since the last medication, the garenoxacin concentration in our patient was higher than that reported value, suggesting that accumulation may occur in patients with renal insufficiency after multiple administrations, which can lead to adverse reactions.…”